<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Profile of antivirals investigated for COVID-19 treatment in clinical trials or 
   <italic>in vitro</italic> studies. Source: WHO, adapted from landscape analysis 17 February 2020 
   <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key" id="intref0060" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/blueprint/priority-diseases/key</ext-link>
  </p>
 </caption>
 <alt-text id="alttext0025">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Group</th>
    <th>Drugs</th>
    <th>Structure and PubChem CID</th>
    <th>Route of administration</th>
    <th>Current use</th>
    <th>Mechanism of action</th>
    <th>EC
     <sub>50</sub> value in Vero E6 cell
    </th>
    <th>Being tested?</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">
     <bold>Inhibitors of viral RNA polymerase/RNA synthesis</bold>
    </td>
    <td>Remdesivir</td>
    <td>PubChem CID:121304016
     <break/>
     <inline-graphic xlink:href="fx1_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0030">Image 1</alt-text>
     </inline-graphic>
    </td>
    <td>Intravenous</td>
    <td>COVID-19</td>
    <td>A prodrug, adenosine nucleotide analogue, which acts as an RdRp inhibitor</td>
    <td>1.76 μM</td>
    <td>Approved</td>
   </tr>
   <tr>
    <td>Favipiravir</td>
    <td>PubChem CID:492405
     <break/>
     <inline-graphic xlink:href="fx2_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0035">Image 2</alt-text>
     </inline-graphic>
    </td>
    <td>Intravenous</td>
    <td>influenza</td>
    <td>A prodrug, guanosine nucleotide analogue, which acts as an RdRp inhibitor</td>
    <td>61.88 μM</td>
    <td>Yes</td>
   </tr>
   <tr>
    <td>
     <bold>Inhibitors of viral protein synthesis</bold>
    </td>
    <td>Lopinavir/ritonavir</td>
    <td>PubChem CID:11979606
     <break/>
     <inline-graphic xlink:href="fx3_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0040">Image 3</alt-text>
     </inline-graphic>
    </td>
    <td>Orally</td>
    <td>HIV</td>
    <td>Inhibition of protease</td>
    <td>26.62 μM</td>
    <td>Yes</td>
   </tr>
   <tr>
    <td rowspan="2">
     <bold>Viral entry inhibitors</bold>
    </td>
    <td>Hydroxychloroquine</td>
    <td>PubChem CID:3652
     <break/>
     <inline-graphic xlink:href="fx4_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0045">Image 4</alt-text>
     </inline-graphic>
    </td>
    <td>Orally</td>
    <td>Antimalarial</td>
    <td rowspan="2">Increase the endosomal pH required by the virus/Cell fusion, and interference Glycosylation of SARS-CoV (ACE-2) cell receptor</td>
    <td>4.51 μM</td>
    <td>yes</td>
   </tr>
   <tr>
    <td>Chloroquine</td>
    <td>PubChem CID:2719
     <break/>
     <inline-graphic xlink:href="fx5_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0050">Image 5</alt-text>
     </inline-graphic>
    </td>
    <td>Orally</td>
    <td>Antimalarial</td>
    <td>2.71 μM</td>
    <td/>
   </tr>
   <tr>
    <td rowspan="2">
     <bold>Immunomodulatory</bold>
    </td>
    <td>Nitazoxanide</td>
    <td>PubChem CID:41684
     <break/>
     <inline-graphic xlink:href="fx6_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0055">Image 6</alt-text>
     </inline-graphic>
    </td>
    <td>Orally</td>
    <td>Anti-parasitic and antiviral</td>
    <td>Interference involves viral replication, amplification of cytoplasmic RNA sensing, and host regulation pathways of type I interferon</td>
    <td>2.12 μM</td>
    <td>yes</td>
   </tr>
   <tr>
    <td>Ivermectin</td>
    <td>PubChem CID:6321424
     <break/>
     <inline-graphic xlink:href="fx7_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0060">Image 7</alt-text>
     </inline-graphic>
    </td>
    <td>Orally</td>
    <td>Anti-parasitic</td>
    <td>Inhibit the import of nuclear proteins into hosts and viruses by suppressing importin 1 Heterodimer</td>
    <td>NA</td>
    <td>yes</td>
   </tr>
   <tr>
    <td>
     <bold>Immunomodulatory</bold>
    </td>
    <td>Tocilizumab</td>
    <td>NA</td>
    <td>Intravenously</td>
    <td>Rheumatoid arthritis; COVID-19</td>
    <td>inhibit signal transduction by specifically binding to sIL-6R and mIL-6R</td>
    <td>NA</td>
    <td>Approved</td>
   </tr>
   <tr>
    <td>
     <bold>Anti-inflammatory</bold>
    </td>
    <td>Dexamethasone</td>
    <td>
     <inline-graphic xlink:href="fx8_lrg.gif" xmlns:xlink="http://www.w3.org/1999/xlink">
      <alt-text id="alttext0065">Image 8</alt-text>
     </inline-graphic>
    </td>
    <td>Intravenously and orally</td>
    <td>Anti-inflammatory</td>
    <td>Act as an inflammatory agent</td>
    <td>NA</td>
    <td>yes</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Note: Not applicable- NA.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
